Skip to main content
All lobbying filings

Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated filed a Q2 report for Vertex Pharmaceuticals Incorporated on July 16, 2025.

Lobbying for Vertex Pharmaceuticals Incorporated

As filed: VERTEX PHARMACEUTICALS INCORPORATED for VERTEX PHARMACEUTICALS INCORPORATED.

All filings by Vertex Pharmaceuticals Incorporated · Everything Vertex Pharmaceuticals Incorporated has reported

 Amended
The filer submitted a later report covering this same period, so the amounts here have been replaced. Site totals count only the latest version. See the current filing, posted Oct 9, 2025.
 Filing · LD-2 quarterly report Q2 report
Reporting period
2nd Quarter 2025
Apr 1 - June 30 · Posted Jul 16, 2025
Expenses
$1,140,000
What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
Massachusetts

Official filing document

 Government bodies contacted 11

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 6
Health Issues

Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, S.864 - HELP Copays Act; Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; General education about kidney disease, including APOL-1; Cystic Fibrosis; Sickle cell disease; Innovations in Type 1 diabetes treatments.

Medicare/Medicaid

Unmet medical need in acute pain; H.R. 1227/S. 475 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning; CMMI demo focusing on sickle cell disease; Drug Pricing Policies including Most Favored Nation policy proposals; Issues regarding the One Big Beautiful Bill Act (PL 119-21).

Taxation/Internal Revenue Code

Corporate tax reform; H.R. 1414 - Cameron's Law, Preservation of Orphan Drug Tax Credit; Restoration of Sec 174 R&D Expense Deductibility; Issues related to the One Big Beautiful Bill Act (PL 119-21).

Budget/Appropriations

Education about non-opioid pain therapies and patient access to non-opioid medicines; Education on alternative funding programs; Education on the Million Veteran Program at the VA.

Trade (domestic/foreign)

Intellectual property reforms to address unfair trade practices in Argentina and Russia.

Pharmacy

Issues related to the National Defense Authorization Act - access to non-opioids for service members and their families.

 Bills named in this filing 4

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem